Sang-Ho Choi1, Allison L Arai1, Yongshan Mou1, Byeongteck Kang1, Cecil Chern-Chyi Yen1, John Hallenbeck1, Afonso C Silva2. 1. From the Cerebral Microcirculation Section, Laboratory of Functional and Molecular Imaging (S.-H.C., A.A., C.C.-C.Y., A.C.S.); National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD (Y.M., J.H.); and College of Veterinary Medicine, Chungbuk National University, Cheongju, Korea (B.K.). 2. From the Cerebral Microcirculation Section, Laboratory of Functional and Molecular Imaging (S.-H.C., A.A., C.C.-C.Y., A.C.S.); National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD (Y.M., J.H.); and College of Veterinary Medicine, Chungbuk National University, Cheongju, Korea (B.K.). silvaa@ninds.nih.gov.
Abstract
BACKGROUND AND PURPOSE: MAGL (monoacylglycerol lipase) is an enzyme that hydrolyzes the endocannabinoid 2-arachidonoylglycerol and regulates the production of arachidonic acid and prostaglandins-substances that mediate tissue inflammatory response. Here, we have studied the effects of the selective MAGL inhibitors JZL184 and MJN110 and their underlying molecular mechanisms on 3 different experimental models of focal cerebral ischemia. METHODS: SHR (spontaneously hypertensive rats) and normotensive WKY (Wistar Kyoto) rats were subject to an intracortical injection of the potent vasoconstrictor endothelin-1, permanent occlusion of a distal segment of the middle cerebral artery via craniectomy, or transient occlusion of the middle cerebral artery by the intraluminal suture method. JZL184 or MJN110 was administered 60 minutes after focal cerebral ischemia. Infarct volumes, hemispheric swelling, and functional outcomes were assessed between days 1 to 28 by magnetic resonance imaging, histology, and behavioral tests. RESULTS: Pharmacological inhibition of MAGL significantly attenuated infarct volume and hemispheric swelling. MAGL inhibition also ameliorated sensorimotor deficits, suppressed inflammatory response, and decreased the number of degenerating neurons. These beneficial effects of MAGL inhibition were not fully abrogated by selective antagonists of cannabinoid receptors, indicating that the anti-inflammatory effects are caused by inhibition of eicosanoid production rather than by activation of cannabinoid receptors. CONCLUSIONS: Our results suggest that MAGL may contribute to the pathophysiology of focal cerebral ischemia and is thus a promising therapeutic target for the treatment of ischemic stroke.
BACKGROUND AND PURPOSE:MAGL (monoacylglycerol lipase) is an enzyme that hydrolyzes the endocannabinoid2-arachidonoylglycerol and regulates the production of arachidonic acid and prostaglandins-substances that mediate tissue inflammatory response. Here, we have studied the effects of the selective MAGL inhibitors JZL184 and MJN110 and their underlying molecular mechanisms on 3 different experimental models of focal cerebral ischemia. METHODS: SHR (spontaneously hypertensiverats) and normotensive WKY (Wistar Kyoto) rats were subject to an intracortical injection of the potent vasoconstrictor endothelin-1, permanent occlusion of a distal segment of the middle cerebral artery via craniectomy, or transient occlusion of the middle cerebral artery by the intraluminal suture method. JZL184 or MJN110 was administered 60 minutes after focal cerebral ischemia. Infarct volumes, hemispheric swelling, and functional outcomes were assessed between days 1 to 28 by magnetic resonance imaging, histology, and behavioral tests. RESULTS: Pharmacological inhibition of MAGL significantly attenuated infarct volume and hemispheric swelling. MAGL inhibition also ameliorated sensorimotor deficits, suppressed inflammatory response, and decreased the number of degenerating neurons. These beneficial effects of MAGL inhibition were not fully abrogated by selective antagonists of cannabinoid receptors, indicating that the anti-inflammatory effects are caused by inhibition of eicosanoid production rather than by activation of cannabinoid receptors. CONCLUSIONS: Our results suggest that MAGL may contribute to the pathophysiology of focal cerebral ischemia and is thus a promising therapeutic target for the treatment of ischemic stroke.
Authors: Daniel K Nomura; Bradley E Morrison; Jacqueline L Blankman; Jonathan Z Long; Steven G Kinsey; Maria Cecilia G Marcondes; Anna M Ward; Yun Kyung Hahn; Aron H Lichtman; Bruno Conti; Benjamin F Cravatt Journal: Science Date: 2011-10-20 Impact factor: 47.728
Authors: Paige S Katz; Jesse K Sulzer; Renata A Impastato; Sophie X Teng; Emily K Rogers; Patricia E Molina Journal: J Neurotrauma Date: 2014-12-19 Impact factor: 5.269
Authors: Matilda Degn; Kate L Lambertsen; Gitte Petersen; Michael Meldgaard; Andreas Artmann; Bettina H Clausen; Steen H Hansen; Bente Finsen; Harald S Hansen; Trine M Lund Journal: J Neurochem Date: 2007-09-14 Impact factor: 5.372
Authors: Larisa V Lysenko; Jeesun Kim; Cassandra Henry; Anna Tyrtyshnaia; Rebecca A Kohnz; Francisco Madamba; Gabriel M Simon; Natalia E Kleschevnikova; Daniel K Nomura; R Alan B Ezekowitz; Alexander M Kleschevnikov Journal: PLoS One Date: 2014-12-04 Impact factor: 3.240
Authors: Jonathan Z Long; Weiwei Li; Lamont Booker; James J Burston; Steven G Kinsey; Joel E Schlosburg; Franciso J Pavón; Antonia M Serrano; Dana E Selley; Loren H Parsons; Aron H Lichtman; Benjamin F Cravatt Journal: Nat Chem Biol Date: 2008-11-23 Impact factor: 15.040
Authors: Karen Jaqueline Paredes-Ruiz; Karla Chavira-Ramos; Mario Orozco-Morales; Cimen Karasu; Alexey A Tinkov; Michael Aschner; Abel Santamaría; Ana Laura Colín-González Journal: Neurotox Res Date: 2021-11-06 Impact factor: 3.911
Authors: Xiaodong Zhang; Yumei Yan; Frank Tong; Chun-Xia Li; Benjamin Jones; Silun Wang; Yuguang Meng; E Chris Muly; Doty Kempf; Leonard Howell Journal: Open Neuroimag J Date: 2018-03-30